Orthocell Ltd
ASX:OCC
Intrinsic Value
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. [ Read More ]
The intrinsic value of one OCC stock under the Base Case scenario is 0.52 AUD. Compared to the current market price of 0.39 AUD, Orthocell Ltd is Undervalued by 25%.
Valuation Backtest
Orthocell Ltd
Run backtest to discover the historical profit from buying and selling OCC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Orthocell Ltd
Current Assets | 21.7m |
Cash & Short-Term Investments | 19.6m |
Receivables | 861k |
Other Current Assets | 1.2m |
Non-Current Assets | 3.3m |
PP&E | 2.2m |
Intangibles | 1.1m |
Current Liabilities | 4.7m |
Accounts Payable | 1.3m |
Accrued Liabilities | 974.8k |
Other Current Liabilities | 2.4m |
Non-Current Liabilities | 18m |
Long-Term Debt | 616.7k |
Other Non-Current Liabilities | 17.4m |
Earnings Waterfall
Orthocell Ltd
Revenue
|
6.1m
AUD
|
Cost of Revenue
|
-1.4m
AUD
|
Gross Profit
|
4.7m
AUD
|
Operating Expenses
|
-15.3m
AUD
|
Operating Income
|
-10.6m
AUD
|
Other Expenses
|
3.2m
AUD
|
Net Income
|
-7.4m
AUD
|
Free Cash Flow Analysis
Orthocell Ltd
OCC Profitability Score
Profitability Due Diligence
Orthocell Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Orthocell Ltd's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
OCC Solvency Score
Solvency Due Diligence
Orthocell Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Orthocell Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCC Price Targets Summary
Orthocell Ltd
According to Wall Street analysts, the average 1-year price target for OCC is 0.56 AUD with a low forecast of 0.56 AUD and a high forecast of 0.58 AUD.
Shareholder Return
OCC Price
Orthocell Ltd
Average Annual Return | 79.26% |
Standard Deviation of Annual Returns | 170.6% |
Max Drawdown | -69% |
Market Capitalization | 77.7m AUD |
Shares Outstanding | 209 327 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
Contact
IPO
Employees
Officers
The intrinsic value of one OCC stock under the Base Case scenario is 0.52 AUD.
Compared to the current market price of 0.39 AUD, Orthocell Ltd is Undervalued by 25%.